← Back to all trials
Recruiting
NCT05630378
Evaluation of an Integrative Medicine Outpatient Clinical Setting for Post-COVID-19 Patients
Conditions: COVID-19, Fatigue
Sex: All
Ages: 18 Years – 75 Years
Phase: NA
Enrollment: 42
Sponsor: Universität Duisburg-Essen
Location: Germany
Summary
The study aims to identify whether a multimodal integrative naturopathy outpatient clinical concept can improve the symptoms of patients suffering from post-COVID-Syndrome. Main outcome is fatigue.
The outpatient clinical programme consists of 11 weeks wherein patients visit the clinic one day per week.
The pillars of classical naturopathy are combined with extended naturopathy and complementary procedures.
Previous naturopathical studies on patients with chronic fatigue syndrome could find numerous indications that different types of naturopathy can help patients with fatigue.
Eligibility Criteria
Inclusion Criteria:18 to 75 years of agediagnosed with post covid syndromefatigue with or without myalgiasigned declaration of consentExclusion Criteria:contraindications for whole body infrared hyperthermia (severe cardiovascular diseases, tumour diseases, acute infections, pregnant and breastfeeding women)Acute and or feverish microbially infectionsPleuritic chest painRelevant shortness of breathZn Critical illness or intensive medical care because of COVID 19Patients with severe somatic, cardiovascular pneumological, rheumatic, endocrine or neurological comorbidities.
Especially neurological disorders accompanied by cognitive impairment, severe liver or kidney disorders.Patients permanently treated with opioids, cannabis, immunosuppressive agents (e.g.
corticoids, immunsuppressives) or alpha/beta-a(nta)gonistsPatients with pain as a consequence of a severe psychiatric disease (bipolar disorder, psychosis, personality disorder, severe depression, substance abuse) as well as severe systematic disorders or neurological disordersParticipation in other clinical studies
Source: ClinicalTrials.gov (NCT05630378). StuddyBuddy aggregates publicly available trial information.